Icon
+91 94997 68112
Login Register

Onexton - (3.75%; EQ 1.2% BASE; Gel, Topical)

Clindamycin Phosphate and Benzoyl Peroxide Dow Pharma
3.75%; EQ 1.2% BASE; Gel, Topical
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
Less Than 5
Less Than 5
once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older
Yes
*** (****) ** *** ***** ** **** **** ** **** ******* '*** (*** *, ****), '*** *** '*** **** ******** ** *** *, **** *** *** ************ *********. ******* ******* *** ******* **** ***** **** ** **** *** **** ******* *** **** ************ *********. ********** ** ******* **** *** *** ***** ********* ***** *** ***** ** ********** *** *** ***** *** ** ****** ***(****) ** ****** ****** ** ***** ** * ******* ****** ***** *** *** **** *** *** ** ********** ****** *** ******** *** ** ***** ** **** **** ********* ** **********. ******* *** ******* **** ****** * ****** ***** ***(****). ******** **** ******** ****** ** ***** ************** *** ***** **** ******* **** *** ********* ******* ***********. ********* ** *** ******, ****** ******* **** ** ****** *********** *** ******* ** ****. **** ** ****** *** ********** ****** *** ******** ** ****** ** ** ****.
Onexton Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
*** (****) ******* ******* ******* ******* ******* ******* ******* *******
******* ******* ******* ******* ******* ******* ******* ******* *******
******* ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** (****) *** \ *** **** **, **** ******* ******** ******** ** *** **, ****
******* ** \ ** *** **, **** ******* ********* ******** ***** ***-**** ***********
******* ** \ ** *** *, **** ******* ********* ******** ***** ***-**** ***********
  1. *** *, **** : **** ******** ******* *** *** ****** ***** *** **** ** **** ****** ***,***,*** (*** *, ****).
  2. *** **, **** : ******* *** *** ***** * **** ******* **** ** ******** ***** ** **.
  3. *** **, **** : ******* ***** * **** ******* **** ** **** ***** **** ** **** ****** '*** (*** *, ****).
  4. *** **, **** : ******* ***** * **** ******* ******* ** ******* ***** **** ** **** ****** '*** (*** *, ****).
  5. *** *, **** : ******* ***** * **** ******* ******* ** ******* ***** **** ** **** ******* '*** (*** *, ****); '*** (*** *, ****).
  6. *** **, **** : **** ******** *** ***** *** **** ** **** ** ****** ***,***,*** (*** **, ****) .
  7. *** *, **** : ******* ******** *** ***** *** **** ** **** ** ******* ***,***,*** (*** *, ****) *** '*** (*** **,****)
  8. *** *, **** : *** **** **** ** ** ** **.
  9. *** **, **** : *** **** ******* ** ** ** **
  10. *** **, **** : ********** *** ********* **** ******* ***** *** ***** ** ********* *** *** *****. ** ****** ** *** * **********.
  11. *** **, **** : ********** *** ********* **** ******* ***** *** ***** ** ********* *** *** *****. ** ****** ** *** * **********.
  12. *** **, **** : ********** ********* **** *** ****** *** *** *** ******* ** **** ***** *** ***** ** ********* *** *** *****. ** ****** ** *** * **********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.